Sector News

AZ signs deal with Europe’s IVA for coronavirus vaccine supply

June 16, 2020
Life sciences

AstraZeneca has agreed with Europe’s Inclusive Vaccines Alliance (IVA) that it will supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine to broaden access in the region.

The deal, which will see deliveries start by the end of this year, allows the IVA aims to accelerate the supply of the vaccine and to make it available to other European countries that wish to participate in the initiative.

“This agreement will ensure that hundreds of millions of Europeans have access to Oxford University’s vaccine following approval,” said Pascal Soriot, AZ’ chief executive.

“With our European supply chain due to begin production soon, we hope to make the vaccine available widely and rapidly. I would like to thank the governments of Germany, France, Italy and the Netherlands for their commitment and swift response.”

AstraZeneca is currently working on establishing a number of supply chains in parallel across the world, including for Europe, with total manufacturing capacity currently at two billion doses.

Oxford University has recently begun testing AZD1222 in a Phase II/III UK trial involving around 10,000 adult volunteers, and other late-stage trials are due to begin in a number of countries.

By: Selina McKee

Source: Pharma Times

comments closed

Related News

November 27, 2022

DSM-Firmenich nutrition and beauty mega-merger edges closer as companies announce Exchange Offer

Life sciences

The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.

November 27, 2022

Merck agrees to acquire Imago for $1.35bn

Life sciences

Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.

November 27, 2022

Novo Nordisk expands API capacity

Life sciences

Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.